Peer-Reviewed Study Reports on New Blood Test for Early Breast Cancer Detection

Why it matters locally: While not specific to Connecticut, advances in early cancer detection, such as this new blood test, could impact healthcare practices and patient outcomes across the state as medical facilities evaluate new screening tools.

---

SAINT PAUL, Minn. – Researchers published a new peer-reviewed study detailing the capabilities of a blood test for early-stage breast cancer detection. The study appeared in a scientific journal on July 30, 2026. The authors, affiliated with Astrin Biosciences, reported the test demonstrated a sensitivity exceeding 92% and a specificity exceeding 92%. These metrics, they indicate, surpass the performance of current supplemental screening standards. Astrin Biosciences, a company focused on cancer detection and treatment, developed the test. Researchers developed the blood test using deep proteomics, a method involving the large-scale study of proteins. The company states this technology enables the analysis of numerous proteins within a blood sample. This analysis aims to identify early indicators of breast cancer.